CPH expands its footprint with new product launch and entry into Eastern Europe
Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.
In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.
The below articles were written under our previous business model. We have kept these articles online here for your reference.
Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.
Click Here to View Latest Articles
It has been a big week for Creso Pharma (ASX: CPH).
This week the company made three important announcements:
- Wholly owned subsidiary Mernova Medicinal Inc. was awarded Craft Designation by the Ontario Cannabis Store (OCS).
- CPH has finalised the development of anibidiol® swine, a new and innovative hemp flour and oat bran based complementary feed product.
- CPH will enter the Polish animal health market after signing a Letter of Intent with Polvet Healthcare Teodorowski Spółka Jawna.
It all started on Monday when wholly-owned Canadian subsidiary Mernova Medicinal Inc., one of a select group of licensed cannabis producers, was awarded Craft Designation by the Ontario Cannabis Store (OCS).
OCS is owned by the Province of Ontario and reports directly to the Ministry of Finance. It is the province’s only retailer and wholesaler of legal recreational cannabis.
This designation is an important in that it will provide Creso Pharma with much broader visibility in a competitive market, while highlighting the superior quality of Mernova’s products as the company continues to achieve strong sales growth across Ontario.
On Wednesday, CPH finalised the development of anibidiol® swine, a hemp flour and oat bran based complementary feed product designed to support stress reduction and well-being with pigs reared indoors and outdoors.
The new product is part of CPH’s strategic portfolio expansion and provides it with an entry point into the livestock market.
anibidiol® swine was developed to address tail biting in pig herds, which is a common problem and can result in lesions that may decrease the value of the animal at slaughter.
A common cause of tail biting is stressor discomfort, with the action diverting the animal’s attention.
anibidiol® swine is designed to help alleviate that stress.
Previous reports have shown a positive impact when using hemp plants to reduce pig stress and pig tail biting.
The livestock and swine feed market provides a very lucrative opportunity for CPH. IMARC Group expects the global swine feed market to reach a value of US$170 Billion (AU$218) by 2026, with a population of over 150 million pigs in Europe and 67 million pigs in Latin America.
anibidiol®swine was developed to address the large need expressed by farmers for an effective, natural and plant based complementary feed to support the reduction of stress and swine tail biting,” CPH’s Commercial and Development Director, Dr. Gian Trepp said.
“The development follows considerable work undertaken by the Creso Pharma team and we are very pleased to have this product ready for launch on a global basis. We anticipate that the launch will provide access into another lucrative vertical for the Company and contribute to the Company’s growing revenue streams.”
Strong finish to the week
The company has finished the week strongly.
CPH announced this morning that has signed a non-binding, non-exclusive Letter of Intent (LOI) to progress a commercial agreement with Polvet to market and distribute its animal health products for companion animals and livestock in Poland.
The agreement will expand CPH’s European footprint and marks its first entry into Eastern Europe.
Polvet will distribute CPH’s anibidiol® granules hemp flour based, oils for pets and anibidiol® hemp flour based for large companion animals and livestock.
Polish representation could be big for CPH, with the country being one of the largest pet markets in the Central-Eastern European region. The Polish animal health market more broadly is substantial and based on 7.7 million dogs, 6.6 million cats, and 11 million swine.
The agreement covers the following Creso Pharma products:
- anibidiol® 8
- anibidiol® dogs treats
- anibidiol ® EQUI
- anibidiol® SWINE
The initial term of the Polvet agreement is for one year.
“We are very proud to announce this new commercial relationship with Polvet Poland, which has been operating in animal and human health for over a decade, representing a perfect fit for both companies to expand operations into the Polish market,” CEO of Swiss International Operations, Jorge Wernli, said.
“This is a key milestone entry into a growing economy and a first step to strengthen Creso’s presence in Eastern Europe.”
tagsANIMAL HEALTH SECTOR ANIBIDIOL CANNABIS AND HEMP DERIVED PRODUCTS CANNABIS PRODUCTS ANIMAL HEALTH PRODUCTS
General Information Only
S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.
Conflicts of Interest Notice
S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.
Publication Notice and Disclaimer
The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.
Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.
This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.